Focused Issue on Diffuse Large B-Cell Lymphoma

Posted On 2019-07-03 03:15:44

This issue, guest-edited by Dr. Astrid Pavlovsky, aims to provide a significantcontribution to the ongoing understanding of diffuse large B-cell lymphoma

Novel markers for determining risk and evaluation of minimal residual disease in diffuse large B-cell lymphoma
Vincent Camus, Sydney Dubois, Fabrice Jardin, Hervé Tilly

Diffuse large B-cell lymphoma—who should we FISH?
Deborah M. Stephens, Sonali M. Smith

Aggressive B-cell lymphomas—from morphology to molecular pathogenesis
Bo-Jung Chen, Falko Fend, Elias Campo, Leticia Quintanilla-Martinez

Immunotherapy in non-Hodgkin lymphoma
Caron A. Jacobson, Philippe Armand

To be published soon
Doble expressor DLBCL: Should this subgroup of patients be treated differently?
Risk stratification and management algorithms for DLBCL with CNS involvement
New drugs for the managment of Relapsed Refractory DLBCL

Astrid Pavlovsky, MD
Medical Director Pavlovsky Center for Hematology Buenos Aires, Argentina

Since 2003 she is working as a staff in the onco hematology department in FUNDALEU where she also participates in different clinical investigational trials as principal investigator or co- investigator. She is also Medical Director of an outpatient clinic dedicated only to hematological patients.

Since 2005 she has been an active member of GATLA (an Argentinean cooperative group) and is currently the Academic Secretary and Chairman of the Lymphoma Study group. She is involved in several educational activities including workshops and university courses. Since 2011 she is involved as a speaker and discussant in the European School of Oncology (ESO) e-grounds for on line education and has recently joined de Lymphoma Hub to promote hematological knowledge. She received the certificate of Competence in Lymphomas from the ULM University in Germany in 2016.

In 2017 she is being part of the Advisory board of the International Congress on Malignant Lymphomas held in Lugano, Switzerland.